Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
Neurocrine(NBIX) stock is priced at $153.55, giving the company a market capitalization of 15.61B. It carries a P/E multiple of 22.57.
As of 2026-08-31, Neurocrine(NBIX) stock has fluctuated between $151.77 and $154.50. The current price stands at $153.55, placing the stock +1.2% above today's low and -0.6% off the high.
Neurocrine(NBIX) shares are trading with a volume of 524.92K, against a daily average of 1.04M.
During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.
During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.
NBIX News
Neurocrine Biosciences NBIX continues to rely heavily on its blockbuster VMAT2 inhibitor, Ingrezza, for top-line growth. Still, the company is making meaningful...
Advertisement FDA milestone puts Neurocrine Biosciences in focus The FDA’s acceptance of Neurocrine Biosciences (NBIX) Investigational New Drug application fo...
Neurocrine Biosciences has reported Phase 4 KINECT-PRO results showing once-daily INGREZZA (valbenazine) led to substantial, sustained improvements in tardive d...
Analyst ratings
90%
of 30 ratingsMore NBIX News
Sosei Group ( (JP:4565) ) has provided an update. Nxera Pharma’s partner Neurocrine Biosciences has secured FDA IND acceptance for a Phase 2 trial of NBI-11175...
Neurocrine Biosciences stock has delivered a 59.0% return over the past five years, yet its current valuation checks still lean on the cheap side rather than pr...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.